| scholarly article | Q13442814 |
| P2093 | author name string | Makio Kobayashi | |
| Noboru Saito | |||
| Shingo Kameoka | |||
| Eiichiro Noguchi | |||
| P2860 | cites work | Examination of transforming growth factor beta1 expression in the serum and tumor tissue of gastric cancer | Q82676038 |
| Clinical significance of fibronectin expression in colorectal cancer | Q83820405 | ||
| Molecular cloning and expression of human hepatocyte growth factor | Q24305558 | ||
| Identification of the Hepatocyte Growth Factor Receptor As the c- met Proto-Oncogene Product | Q24310794 | ||
| Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor | Q24564783 | ||
| Structure and function of hepatocyte growth factor | Q28274665 | ||
| Sema4D induces angiogenesis through Met recruitment by Plexin B1 | Q28301113 | ||
| Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study | Q33416122 | ||
| c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention | Q34422211 | ||
| Activation of hepatocyte growth factor-met autocrine loop enhances tumorigenicity in a human lung adenocarcinoma cell line. | Q34785157 | ||
| RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma | Q35146597 | ||
| Hepatocyte growth factor, its receptor, and their potential value in cancer therapies | Q35988495 | ||
| Increase in the circulating level of hepatocyte growth factor in gastric cancer patients | Q36116145 | ||
| Clinical significance of keratinocyte growth factor and K-sam gene expression in gastric cancer | Q36858565 | ||
| Purification and characterization of a growth factor from rat platelets for mature parenchymal hepatocytes in primary cultures | Q37397472 | ||
| Regulation of cell movement: the motogenic cytokines | Q37699401 | ||
| Hepatocyte growth factor twenty years on: Much more than a growth factor | Q37825664 | ||
| Identity of a tumor cytotoxic factor from human fibroblasts and hepatocyte growth factor | Q39101924 | ||
| Tumor-stromal cell interaction under hypoxia increases the invasiveness of pancreatic cancer cells through the hepatocyte growth factor/c-Met pathway | Q40228024 | ||
| c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions | Q40626106 | ||
| A novel germ line juxtamembrane Met mutation in human gastric cancer | Q40847293 | ||
| Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene | Q40861413 | ||
| Molecular therapy for gastric cancer | Q41116457 | ||
| Immunohistochemical detection of K-sam protein in stomach cancer | Q41176884 | ||
| Purification and subunit structure of hepatocyte growth factor from rat platelets | Q42806247 | ||
| Abnormal expression of E-cadherin in tumor cells is associated with poor prognosis of gastric carcinoma | Q43506625 | ||
| Up-regulated expression of Ezrin and c-Met proteins are related to the metastasis and prognosis of gastric carcinomas | Q44740860 | ||
| Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas | Q45345804 | ||
| The overexpression of c-met as a prognostic indicator for gastric carcinoma compared to p53 and p21 nuclear accumulation | Q46580742 | ||
| The relation between the growth patterns of gastric carcinoma and the expression of hepatocyte growth factor receptor (c-met), autocrine motility factor receptor, and urokinase-type plasminogen activator receptor | Q48017929 | ||
| Japanese Classification of Gastric Carcinoma - 2nd English Edition - | Q51050338 | ||
| p53 mutation pattern and expression of c-erbB2 and c-met in gastric cancer: relation to histological subtypes, Helicobacter pylori infection, and prognosis. | Q53392449 | ||
| Overexpression of the c-met protooncogene in human gastric carcinoma--correlation to clinical features. | Q53394919 | ||
| Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats | Q60034429 | ||
| Prognostic value of vascular endothelial growth factor expression in gastric carcinoma | Q71018131 | ||
| Significant correlation between serum level of hepatocyte growth factor and progression of gastric carcinoma | Q73030399 | ||
| The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas | Q77386062 | ||
| Serum hepatocyte growth factor level associate with gastric cancer progression | Q77687032 | ||
| Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas | Q77931840 | ||
| Clinical significance of epidermal growth factor (EGF) expression in gastric cancer | Q80606855 | ||
| Modulation of E-cadherin by hepatocyte growth factor induces aggressiveness of gastric carcinoma | Q81392233 | ||
| P433 | issue | 5 | |
| P304 | page(s) | 3423-3431 | |
| P577 | publication date | 2015-01-15 | |
| P1433 | published in | Molecular Medicine Reports | Q26842180 |
| P1476 | title | Clinical significance of hepatocyte growth factor/c-Met expression in the assessment of gastric cancer progression | |
| P478 | volume | 11 |
| Q36333585 | A plasma cytokine and angiogenic factor (CAF) analysis for selection of bevacizumab therapy in patients with metastatic colorectal cancer |
| Q57176090 | Biomarkers of gastric cancer: Current topics and future perspective |
| Q42700876 | Clinical impact of high serum hepatocyte growth factor in advanced non-small cell lung cancer |
| Q89687522 | Clinical significance of various growth factors in patients with different gastric neoplasms |
| Q58555802 | Effect of fluorouracil, leucovorin, and oxaliplatin with or without onartuzumab in epidermal growth factor receptor-2-negative, mesenchymal-epithelial transition-positive gastroesophageal adenocarcinoma: is it a real failure? |
| Q38506084 | Emerging kinase inhibitors of the treatment of gastric cancer |
| Q64893921 | Evolving Management Strategies for Metastatic Esophageal and Gastroesophageal Junction Adenocarcinoma. |
| Q47117947 | Expression of c-Met and hepatocyte growth factor in various gastric pathologies and its association with Helicobacter pylori infection |
| Q37735624 | Hepatocyte growth factor/MET in cancer progression and biomarker discovery |
| Q42003695 | Identifying the Appropriate FISH Criteria for Defining MET Copy Number-Driven Lung Adenocarcinoma through Oncogene Overlap Analysis |
| Q37705824 | MET overexpression, gene amplification and relevant clinicopathological features in gastric adenocarcinoma |
| Q37376230 | PKG II reverses HGF-triggered cellular activities by phosphorylating serine 985 of c-Met in gastric cancer cells |
| Q47406171 | Roles of Fibroblast Activation Protein and Hepatocyte Growth Factor Expressions in Angiogenesis and Metastasis of Gastric Cancer |
| Q36355920 | Upfront molecular testing in patients with advanced gastro-esophageal cancer: Is it time yet? |
| Q92504675 | Volumetric parameters on 18F-FDG PET/CT predict the survival of patients with gastric cancer associated with their expression status of c-MET |
Search more.